Veru (NASDAQ:VERU) Shares Cross Below 200-Day Moving Average – What’s Next?

Veru Inc. (NASDAQ:VERU) shares crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.81 and traded as low as $0.64. Veru shares last traded at $0.68, with a volume of 1,431,955 shares traded.

Analysts Set New Price Targets

VERU has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Veru in a research report on Friday, December 20th. Oppenheimer reissued an “outperform” rating and issued a $5.00 price objective on shares of Veru in a research report on Tuesday, November 5th.

Veru Price Performance

The firm has a market capitalization of $98.93 million, a P/E ratio of -1.41 and a beta of -0.50. The firm has a 50-day moving average price of $0.72 and a two-hundred day moving average price of $0.81.

Veru (NASDAQ:VERU) last announced its quarterly earnings data on Monday, December 16th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. Sell-side analysts predict that Veru Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of VERU. PVG Asset Management Corp grew its position in shares of Veru by 13.1% during the 3rd quarter. PVG Asset Management Corp now owns 636,970 shares of the company’s stock worth $490,000 after buying an additional 73,815 shares in the last quarter. Barclays PLC lifted its stake in Veru by 309.2% in the third quarter. Barclays PLC now owns 184,777 shares of the company’s stock worth $142,000 after acquiring an additional 139,617 shares during the period. Geode Capital Management LLC grew its holdings in Veru by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 2,940,140 shares of the company’s stock worth $2,261,000 after acquiring an additional 131,720 shares in the last quarter. Zacks Investment Management purchased a new stake in shares of Veru in the 3rd quarter worth approximately $25,000. Finally, Jane Street Group LLC boosted its stake in shares of Veru by 142.8% during the third quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock valued at $74,000 after purchasing an additional 56,736 shares in the last quarter. 47.16% of the stock is currently owned by hedge funds and other institutional investors.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.